Targeted drugs for low-differentiated cancer mainly include gefitinib, daclotinib, vomitinib, amitinib and so on. Hypofractionated cancer is a type of adenocarcinoma, and there are more targeted drugs available for treatment, such as gefitinib and other drugs for lung cancer, abatinib and other drugs for gastric cancer, and bevacizumab and other drugs for intestinal cancer. Specifically, it needs to be determined by combining the patient’s tumor type, pathological typing, genetic results and so on. Low-differentiated cancer has a high degree of malignancy and rapid progression, so it is recommended to adopt timely surgery, radiotherapy and other treatments, and if there is a suitable therapeutic target, targeted drugs can be used for treatment. It is recommended that patients choose appropriate treatment methods according to their own conditions under the guidance of doctors and actively treat them in order to avoid delaying their conditions.